Compounds > apomorphine hydrochloride, anhydrous
Page last updated: 2024-11-05

apomorphine hydrochloride, anhydrous

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Apomorphine hydrochloride, anhydrous is a dopamine receptor agonist used to treat Parkinson's disease. It is a synthetic derivative of morphine and is typically administered as a subcutaneous injection or as a nasal spray. Apomorphine hydrochloride, anhydrous acts directly on dopamine receptors in the brain, increasing dopamine levels and improving motor function in patients with Parkinson's disease. It is often used for the treatment of off episodes, which are periods of worsening symptoms that can occur in patients with Parkinson's disease. The compound is also being studied for its potential use in the treatment of other conditions, such as erectile dysfunction and drug addiction. Apomorphine hydrochloride, anhydrous has been shown to be effective in improving motor function in patients with Parkinson's disease, but it can also cause side effects such as nausea, vomiting, and hypotension.'

Cross-References

ID SourceID
PubMed CID9410
CHEMBL ID1616
SCHEMBL ID8524
MeSH IDM0331310

Synonyms (40)

Synonym
apokinon
britaject
apomorphinium chloride
6a.beta.-noraporphine-10, 6-methyl-, hydrochloride
(-)-apomorphine hydrochloride
4h-dibenzo[de,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride, (r)-
n-methylnorapomorphine hydrochloride
apomorphine chloride
314-19-2
6a.beta.-aporphine-10, hydrochloride
nsc-11442
apomorphine, hydrochloride
wln: t c6666 1a q kn & tt & j dq eq k1 & gh
apomorphine hydrochloride anhydrous
PRESTWICK_28
apomorphine hydrochloride (r,-)
(6ar)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol hydrochloride
(r)-(-)-apomorphine hcl
r-(-)-apomorphine hcl
CHEMBL1616
4h-dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride (1:1), (6ar)-
9k13md7a0d ,
(r)-(-)-apomorphine hydrochloride
apomorphine hydrochloride [mi]
6a.beta.-aporphine-10,11-diol hydrochloride
SCHEMBL8524
SKYZYDSNJIOXRL-BTQNPOSSSA-N
apomorphinehydrochloride
(r)-5,6,6a,7-tetrahydro-6-methyl-4h-dibenzo[de,g]quinoline-10,11-diol hydrochloride
AKOS024456928
DTXSID5040598
r-(-)-apomorphine hydrochloride
sr-01000597777
SR-01000597777-1
apomorphine-hcl
(r)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol hydrochloride
J-018414
Q27272658
apomorphine.hcl
apomorphine.hcl, 1mg/ml in methanol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (7)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Replicase polyprotein 1abBetacoronavirus England 1IC50 (µMol)10.00000.00403.43889.5100AID1640022
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)0.52000.00022.45859.9600AID1640021
DRattus norvegicus (Norway rat)Ki0.12180.00010.610010.0000AID61515; AID63032
D(3) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.06950.00030.39075.4000AID381912
D(3) dopamine receptorRattus norvegicus (Norway rat)Ki0.02010.00010.25675.8000AID381912; AID63032
D(1B) dopamine receptorRattus norvegicus (Norway rat)Ki0.00370.00020.24622.0000AID63032
D(4) dopamine receptorRattus norvegicus (Norway rat)Ki0.00370.00020.18872.0000AID63032
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki0.00920.00000.437510.0000AID63032; AID65558
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (40)

Assay IDTitleYearJournalArticle
AID1131816Induction of rotation in rat with unilateral denervation of caudate nucleus at 0.25 mg/kg, sc1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
N-Alkyl derivatives of (+/-)-alpha-methyldopamine.
AID1145924In vivo agonist activity at dopamine receptor in pigeon assessed as induction of pecking behavior administered intramuscularly after 1 hr1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Centrally acting emetics. 10. Rigid dopamine congeners derived from octahydrobenzo[f]quinoline.
AID381916Dopaminergic activity in CD1 mouse tuberculum olfactorium assessed as dopamine turn over at 3.29 umol/kg, sc relative to control2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Synthesis and neuropharmacological evaluation of 2-aryl- and alkylapomorphines.
AID1131645Induction of circling behaviour in sc dosed Sprague-Dawley rat in presence of 5 mg/kg cyproheptadine1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID381913Displacement of [3H]spiperone from rat dopamine D2 receptor in brain striatal membrane2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Synthesis and neuropharmacological evaluation of 2-aryl- and alkylapomorphines.
AID1145930Hypothermic activity in mouse assessed as decrease in rectal temperature at 10 mg/kg, sc measured every 15 mins1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Centrally acting emetics. 10. Rigid dopamine congeners derived from octahydrobenzo[f]quinoline.
AID1131623Induction of emesis in sc dosed dog1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID63032Agonist activity was tested in vitro against Dopamine receptor from rat brain membranes with [3H]ADT-6,7-dihydroxy-2-aminotetralin]1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and structural requirements of N-substituted norapomorphines for affinity and activity at dopamine D-1, D-2, and agonist receptor sites in rat brain.
AID1131642Induction of circling behaviour in sc dosed Sprague-Dawley rat in presence of 0.8 mg/kg haloperidol1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131896Postural effect on caudectomized Swiss albino mouse assessed as time duration of asymmetric posture at 1 mg/kg, ip1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Structure--activity relationships of n-substituted dopamine and 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene analogues: behavioral effects in lesioned and reserpinized mice.
AID1131629Induction of stereotyped behaviour in sc dosed Sprague-Dawley rat1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131631Induction of stereotyped behaviour in sc dosed Sprague-Dawley rat assessed as duration of action1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID381912Displacement of [3H]spiperone from rat recombinant dopamine D3 receptor expressed in SF9 cells2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Synthesis and neuropharmacological evaluation of 2-aryl- and alkylapomorphines.
AID1872390Inhibition of EZH2-EED (unknown origin) protein interaction by FP binding assay2022European journal of medicinal chemistry, Mar-05, Volume: 231Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.
AID1131630Induction of stereotyped behaviour in sc dosed Sprague-Dawley rat assessed as onset of action1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID576507Antiplasmodial activity against Plasmodium falciparum 3D7 infected in RBCs by firefly luciferase reporter gene assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.
AID381915Dopaminergic activity in CD1 mouse striatum assessed as dopamine turn over at 3.29 umol/kg, sc relative to control2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Synthesis and neuropharmacological evaluation of 2-aryl- and alkylapomorphines.
AID1145923In vivo antagonist activity at dopamine receptor in sc dosed mongrel dog assessed as inhibition of apomorphine-induced emesis pretreated for 15 mins followed by apomorphine-challenge measured after 1 hr1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Centrally acting emetics. 10. Rigid dopamine congeners derived from octahydrobenzo[f]quinoline.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1131618Inhibition of 2 Hz electric current-induced cardioaccelerator nerve stimulation in iv dosed cat by cardiotachometer analysis in presence of 0.2 mg/kg, iv haloperidol1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID235518Selectivity which is the ratio of Ki of D2 to the Ki of D1.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and structural requirements of N-substituted norapomorphines for affinity and activity at dopamine D-1, D-2, and agonist receptor sites in rat brain.
AID1131640Induction of circling behaviour in sc dosed Sprague-Dawley rat assessed as onset of action1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1124689Emetic activity in sc dosed dogs assessed as frequency of vomiting for 1 hr1979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Rigid congeners of dopamine based on octahydrobenzo[f]quinoline: peripheral and central effects.
AID65558Dopamine receptor D2 affinity was tested in vitro against corpus striatum from rat brain membranes1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and structural requirements of N-substituted norapomorphines for affinity and activity at dopamine D-1, D-2, and agonist receptor sites in rat brain.
AID381914Selectivity for rat dopamine D3 receptor over rat dopamine D2 receptor2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Synthesis and neuropharmacological evaluation of 2-aryl- and alkylapomorphines.
AID1131641Induction of circling behaviour in sc dosed Sprague-Dawley rat assessed as duration of action1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID61515Dopamine receptor D1 affinity was tested in vitro against corpus striatum from rat brain membranes1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and structural requirements of N-substituted norapomorphines for affinity and activity at dopamine D-1, D-2, and agonist receptor sites in rat brain.
AID1131643Induction of circling behaviour in sc dosed Sprague-Dawley rat in presence of 5 mg/kg aceperone1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131625Induction of pecking in pigeon at 1.62 umol/kg, im1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1145929Toxicity in sc dosed mongrel dog assessed as behavioral changes1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Centrally acting emetics. 10. Rigid dopamine congeners derived from octahydrobenzo[f]quinoline.
AID1131849Postural effect on caudectomized Swiss albino mouse assessed as latency to onset time of asymmetric postural effect at 1 mg/kg, ip1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Structure--activity relationships of n-substituted dopamine and 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene analogues: behavioral effects in lesioned and reserpinized mice.
AID1124691Induction of pecking activity in pigeons assessed as counts for 1 hr1979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Rigid congeners of dopamine based on octahydrobenzo[f]quinoline: peripheral and central effects.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1131639Induction of circling behaviour in sc dosed Sprague-Dawley rat assessed as reversal of spontaneous ipsilateral to contralateral circling response1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131644Induction of circling behaviour in sc dosed Sprague-Dawley rat in presence of 5 mg/kg propranolol1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID191783Stereotyped behavior was tested in rats at (ip) administration of 3 mg/kg (N=6).scores were compared as the percent of that obtained with apomorphine1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and structural requirements of N-substituted norapomorphines for affinity and activity at dopamine D-1, D-2, and agonist receptor sites in rat brain.
AID1131689Agonist activity at dopamine receptor in cat right atrium assessed as inhibition of cardiaccelerator nerve stimulation rate by cardiotachometer analysis1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131615Inhibition of 2 Hz electric current-induced cardioaccelerator nerve stimulation in iv dosed cat by cardiotachometer analysis1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1872383Binding affinity to EZH2-EED (unknown origin) protein interaction assessed as inhibition constant by FP binding assay2022European journal of medicinal chemistry, Mar-05, Volume: 231Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.
AID1131929Reversal of reserpine-induced catalepsy in ip dosed Swiss albino (CD1) mouse1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Structure--activity relationships of n-substituted dopamine and 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene analogues: behavioral effects in lesioned and reserpinized mice.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (50.00)18.7374
1990's1 (10.00)18.2507
2000's1 (10.00)29.6817
2010's2 (20.00)24.3611
2020's1 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.33 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
histamine
[no description available]		2.0510aralkylamino compound;
imidazoles		human metabolite;
mouse metabolite;
neurotransmitter
ethylisopropylamiloride
ethylisopropylamiloride: structure in first source. ethylisopropylamiloride : A member of the class of pyrazines that is amiloride in which the amino substitutent of the pyrazine ring that is adjacent to the chloro substituent has been substituted by an ethyl group and by an isopropyl group.		2.0510aromatic amine;
guanidines;
monocarboxylic acid amide;
organochlorine compound;
pyrazines;
tertiary amino compound		anti-arrhythmia drug;
neuroprotective agent;
sodium channel blocker
astemizole
Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects.. astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position.		3.6320benzimidazoles;
piperidines		anti-allergic agent;
anticoronaviral agent;
H1-receptor antagonist
bufexamac
Bufexamac: A benzeneacetamide with anti-inflammatory, analgesic, and antipyretic action. It is administered topically, orally, or rectally.. bufexamac : A hydroxamic acid derived from phenylacetamide in which the benzene moiety is substituted at C-4 by a butoxy group. It has anti-inflammatory, analgesic, and antipyretic properties.		2.0510aromatic ether;
hydroxamic acid		antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		2.0510aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
cimetidine
Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.		2.0510aliphatic sulfide;
guanidines;
imidazoles;
nitrile		adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
n,n-di-n-propyldopamine
N,N-di-n-propyldopamine: RN given refers to parent cpd		1.9510catecholamine
hycanthone
Hycanthone: Potentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE.. hycanthone : A thioxanthen-9-one compound having a hydroxymethyl substituent at the 1-position and a 2-[(diethylamino)ethyl]amino substituent at the 4-position. It was formerly used (particularly as the monomethanesulfonic acid salt) as a schistosomicide for individual or mass treatement of infection with Schistosoma haematobium and S. mansoni, but due to its toxicity and concern about possible carcinogenicity, it has been replaced by other drugs such as praziquantel.		2.0510thioxanthenesmutagen;
schistosomicide drug
mefloquine hydrochloride
[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol : An organofluorine compound that consists of quinoline bearing trifluoromethyl substituents at positions 2 and 8 as well as a (2-piperidinyl)hydroxymethyl substituent at position 4.		2.0510organofluorine compound;
piperidines;
quinolines;
secondary alcohol
nifedipine
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.		3.5110C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
nizatidine
[no description available]		2.05101,3-thiazoles;
C-nitro compound;
carboxamidine;
organic sulfide;
tertiary amino compound		anti-ulcer drug;
cholinergic drug;
H2-receptor antagonist
oxyphenbutazone
Oxyphenbutazone: A non-steroidal anti-inflammatory drug. Oxyphenbutazone eyedrops have been used abroad in the management of postoperative ocular inflammation, superficial eye injuries, and episcleritis. (From AMA, Drug Evaluations Annual, 1994, p2000) It had been used by mouth in rheumatic disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis but such use is no longer considered justified owing to the risk of severe hematological adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p27). oxyphenbutazone : A metabolite of phenylbutazone obtained by hydroxylation at position 4 of one of the phenyl rings. Commonly used (as its hydrate) to treat pain, swelling and stiffness associated with arthritis and gout, it was withdrawn from the market 1984 following association with blood dyscrasis and Stevens-Johnson syndrome.		3.5110phenols;
pyrazolidines		antimicrobial agent;
antineoplastic agent;
antipyretic;
drug metabolite;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite
periciazine
periciazine: was heading 1963-94 (Prov 1963-72); use PHENOTHIAZINES to search PROPERICIAZINE 1966-94. periciazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by a 3-(4-hydroxypiperidin-1-yl)propyl group at the nitrogen atom and a carbonitrile group at position 2. Periciazine is a first generation antipsychotic.		2.0510hydroxypiperidine;
nitrile;
phenothiazines		adrenergic antagonist;
first generation antipsychotic;
sedative
sulfamerazine
[no description available]		2.0510pyrimidines;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
drug allergen
dextroamphetamine
Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.. (S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.		1.95101-phenylpropan-2-amineadrenergic agent;
adrenergic uptake inhibitor;
dopamine uptake inhibitor;
dopaminergic agent;
neurotoxin;
sympathomimetic agent
vincristine
[no description available]		2.0510acetate ester;
formamides;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent;
drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
apomorphine
Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.		1.9510aporphine alkaloidalpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug
levodopa
Levodopa: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.. L-dopa : An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease		1.9510amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug
quinacrine monohydrochloride
[no description available]		2.0510
benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(n,n-dimethyl-n-2-propenyl-), dibromide
Benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(N,N-dimethyl-N-2-propenyl-), Dibromide: Proposed cholinesterase inhibitor.		2.0510
vinblastine
[no description available]		2.0510
antimycin a
[no description available]		2.0510benzamides;
formamides;
macrodiolide;
phenols		antifungal agent;
mitochondrial respiratory-chain inhibitor;
piscicide
clobetasol propionate
Clobetasol Propionate: This is the form in trademark preparations.. clobetasol propionate : The 17-O-propionate ester of clobetasol. A potent corticosteroid, it is used to treat various skin disorders, including exzema and psoriasis.		2.051011beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
fluorinated steroid;
glucocorticoid		anti-inflammatory drug
ranitidine hydrochloride
label : A role played by a part of a molecular entity distinguishable by the observer but not by the system and used to identify a tracer.		2.0510
tiotidine
tiotidine: UD gives slightly different structure for this cpd; RN given refers to parent cpd; structure in first source		2.0510thiazoles
chloroquine diphosphate
[no description available]		2.0510
epigallocatechin gallate
epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.		3.5110flavans;
gallate ester;
polyphenol		antineoplastic agent;
antioxidant;
apoptosis inducer;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent;
plant metabolite
telmisartan
Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION.. telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension.		2.0510benzimidazoles;
biphenyls;
carboxybiphenyl		angiotensin receptor antagonist;
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
environmental contaminant;
xenobiotic
5-(n-methyl-n-isobutyl)amiloride
5-(N-methyl-N-isobutyl)amiloride: inhibitor of the Na+-H+ antiporter		2.0510
amperozide
amperozide : A member of the class of ureas that is urea in which three of the four hydrogens are replaced by ethyl and 4-[4,4-bis(4-fluorophenyl)butyl]piperazin-1-yl groups. An atypical antipsychotic which was in clinical development for the treatment of schizophrenia and substance-related disorders. It is a potent 5-HT2A antagonist and used in veterinary medicine because of its sedative effect on pigs.		2.0510diarylmethane;
monofluorobenzenes;
N-alkylpiperazine;
secondary carboxamide;
ureas		anxiolytic drug;
dopamine uptake inhibitor;
geroprotector;
second generation antipsychotic;
serotonergic antagonist
amperozide hydrochloride
amperozide hydrochloride : The hydrochloride salt of amperozide.		2.0510hydrochlorideanxiolytic drug;
dopamine uptake inhibitor;
geroprotector;
second generation antipsychotic;
serotonergic antagonist
atovaquone
Atovaquone: A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols.. atovaquone : A naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position.		2.0510hydroxy-1,2-naphthoquinone
2,5-dimethoxy-4-methylamphetamine
2,5-Dimethoxy-4-Methylamphetamine: A psychedelic phenyl isopropylamine derivative, commonly called DOM, whose mood-altering effects and mechanism of action may be similar to those of LSD.		1.9510
cinchonine
[no description available]		2.0510(8xi)-cinchonan-9-ol;
cinchona alkaloid		metabolite
sk&f 95282
zolantidine: structure given in first source		2.0510piperidines
3',4'-dichlorobenzamil
3',4'-dichlorobenzamil: inhibits Na-Ca exchange in membrane vesicle & papillary muscle preparations from guinea pig heart		2.0510guanidines;
pyrazines
ici 162846
ICI 162846: structure given in first source		2.0510fatty amide
n,n-dimethyldopamine
N,N-dimethyldopamine: RN given refers to parent cpd		1.9510
cloperastine hydrochloride
[no description available]		2.0510diarylmethane
aminopotentidine
aminopotentidine: structure given in first source; RN given refers to the oxalate. aminopotentidine : A benzamide obtained by formal condensation of the carboxy group of 4-aminobenzoic acid with the primary amino group of 1-(2-aminoethyl)-2-cyano-3-{3-[3-(piperidin-1-ylmethyl)phenoxy]propyl}guanidine.		2.0510aromatic ether;
benzamides;
guanidines;
nitrile;
piperidines;
substituted aniline		H2-receptor antagonist
mometasone furoate
Mometasone Furoate: A pregnadienediol derivative ANTI-ALLERGIC AGENT and ANTI-INFLAMMATORY AGENT that is used in the management of ASTHMA and ALLERGIC RHINITIS. It is also used as a topical treatment for skin disorders.		2.051011beta-hydroxy steroid;
2-furoate ester;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
organochlorine compound;
steroid ester		anti-allergic agent;
anti-inflammatory drug
quinidine sulfate
[no description available]		2.0510
wedelolactone
wedelolactone: antihepatotoxic coumestan from Eclipta prostrata and Wedelia calendulacea (both Asteraceae); structure given in first source. wedelolactone : A member of the class of coumestans that is coumestan with hydroxy substituents as positions 1, 8 and 9 and a methoxy substituent at position 3.		3.5110aromatic ether;
coumestans;
delta-lactone;
polyphenol		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
hepatoprotective agent;
metabolite
famotidine
[no description available]		2.05101,3-thiazoles;
guanidines;
sulfonamide		anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
ergonovine maleate
ergometrine maleate : A maleate salt resulting form the reaction of equimolar amounts of maleic acid and ergometrine. It is used in the active management of the third stage of labour, and to prevent or treat postpartum of postabortal haemorrhage caused by uterine atony: by maintaining uterine contraction and tone, blood vessels in the uterine wall are compressed and blood flow reduced.		3.5110maleate saltdiagnostic agent;
oxytocic
artesunate
artesunic acid: RN given for (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,(2aR*))-isomer; succinic ester of artemether		2.0510artemisinin derivative;
cyclic acetal;
dicarboxylic acid monoester;
hemisuccinate;
semisynthetic derivative;
sesquiterpenoid		antimalarial;
antineoplastic agent;
ferroptosis inducer
artenimol
artenimol: derivative of antimalarial drug artemisinin (quinghaosu)		2.0510
quinine sulfate
[no description available]		2.0510hydrate
gsk-2816126
GSK-2816126: inhibits EZH2 methyltransferase; structure in first source		3.5110piperazines;
pyridines
osimertinib
osimertinib: an EGFR tyrosine kinase inhibitor. osimertinib : A member of the class of aminopyrimidines that is 4-(1-methylindol-3-yl)pyrimidin-2-amine in which one of the amino hydrogens is replaced by a 2-methoxy-4-[2-(dimethylamino)ethyl](methyl)amino-5-acrylamidophenyl group. Used (as the mesylate salt) for treatment of EGFR T790M mutation positive non-small cell lung cancer.		3.5110acrylamides;
aminopyrimidine;
biaryl;
indoles;
monomethoxybenzene;
secondary amino compound;
secondary carboxamide;
substituted aniline;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
ConditionIndicatedRelationship StrengthStudiesTrials
Anochlesia
[description not available]		01.9510
Benign Neoplasms
[description not available]		03.3310
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		15.3310